Polyclonal Antibody to Sheep COX1 (PTGS1/Cyclooxygenase-1

Total Page：16

File Type：pdf, Size：1020Kb

Polyclonal Antibody to Sheep COX1 (PTGS1/Cyclooxygenase-1

BP051 OriGene Technologies Inc. OriGene EU Acris Antibodies GmbH 9620 Medical Center Drive, Ste 200 Schillerstr. 5 Rockville, MD 20850 32052 Herford UNITED STATES GERMANY Phone: +1-858-888-7900 Phone: +49-5221-34606-0 Fax: +1-858-888-7904 Fax: +49-5221-34606-11 [email protected] [email protected] Polyclonal Antibody to Sheep COX1 (PTGS1/Cyclooxygenase-1) - Serum Alternate names: COX-1, COX1, Cyclooxygenase-1, PGH synthase 1, PGHS-1, PTGS1, Prostaglandin G/H synthase 1, Prostaglandin H2 synthase 1, Prostaglandin-endoperoxide synthase 1 Catalog No.: BP051 Quantity: 1 ml Background: Cytochrome c oxidase subunit I, COX1 (also designated COI, MTCO2 or oxidative phosphorylation (OxPhos) Complex IV, subunit I) is one of three mitochondrial DNA (mtDNA) encoded subunits (MTCO1-3) of respiratory Complex IV. Cytochrome c oxidase is a hetero-oligomeric enzyme composed of 13 subunits localized to the mitochondrial inner membrane and is the terminal enzyme complex of the electron transport chain. Complex IV catalyzes the reduction of molecular oxygen to water. The energy released is used to transport protons across the mitochondrial inner membrane. The resulting electrochemical gradient is necessary for the synthesis of ATP. Complex IV contains 13 polypeptides; COX1, COX2 and COX3 (MTCO1-3) make up the catalytic core and are encoded by mtDNA while subunits IV, Va, Vb, VIa, VIb, VIc, VIIa, VIIb, VIIc and VIII are nuclear-encoded. Uniprot ID: P05979 NCBI: NP_001009476.1 GeneID: 443551 Host: Rabbit Immunogen: Purified COX-1 (PGHS-1) from sheep. Format: State: Liquid Serum containing 0.05% Sodium Azide as preservative. Applications: ELISA: 1/5K-1/20K. Western Blot: 1/50-1/200. Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user. Specificity: Reacts with PGHS-1 from sheep and most other mammalian species. Does not react with rat PGHS-1 or recombinant chicken PGHS-2. Minimal cross reactivity with PGHS-2. Species: Sheep. Other species not tested. Storage: Store the antibody undiluted at 2-8°C for one month or (in aliquots) at -20°C for longer. Avoid repeated freezing and thawing. Shelf life: one year from despatch. For research and in vitro use only. Not for diagnostic or therapeutic work. OG/20121030 Material Safety Datasheets are available at www.acris-antibodies.com or on request. Acris Antibodies is now part of the OriGene family. Learn more at www.origene.com 1 / 1 Powered by TCPDF (www.tcpdf.org).

Copy Link

Recommended publications

Diclofenac Enhances Docosahexaenoic Acid-Induced Apoptosis in Vitro in Lung Cancer Cells
cancers Article Diclofenac Enhances Docosahexaenoic Acid-Induced Apoptosis in Vitro in Lung Cancer Cells Rosemary A. Poku 1, Kylee J. Jones 2, Megan Van Baren 2 , Jamie K. Alan 3 and Felix Amissah 2,* 1 Department of Foundational Sciences, College of Medicine, Central Michigan University, Warriner Hall, 319, Mt Pleasant, MI 48859, USA; [email protected] 2 Department of Pharmaceutical Sciences, Ferris State University, College of Pharmacy, 220 Ferris Dr, Big Rapids, MI 49307, USA; [email protected] (K.J.J.); [email protected] (M.V.B.) 3 Department of Pharmacology and Toxicology, Michigan State University, East Lansing, MI 48824, USA; [email protected] * Correspondence: [email protected]; Tel.: +1-231-591-3790 Received: 9 September 2020; Accepted: 17 September 2020; Published: 20 September 2020 Simple Summary: Polyunsaturated fatty acids (PUFAs) and non-steroidal anti-inflammatory drugs (NSAIDs) have limited anticancer capacities when used alone. We examined whether combining NSAIDs with docosahexaenoic (DHA) would increase their anticancer activity on lung cancer cell lines. Our results indicate that combining DHA and NSAIDs increased their anticancer activities by altering the expression of critical proteins in the RAS/MEK/ERK and PI3K/Akt pathways. The data suggest that DHA combined with low dose diclofenac provides more significant anticancer potential, which can be further developed for chemoprevention and adjunct therapy in lung cancer. Abstract: Polyunsaturated fatty acids (PUFAs) and non-steroidal anti-inflammatory drugs (NSAIDs) show anticancer activities through diverse molecular mechanisms. However, the anticancer capacities of either PUFAs or NSAIDs alone is limited. We examined whether combining NSAIDs with docosahexaenoic (DHA), commonly derived from fish oils, would possibly synergize their anticancer activity.
[Show full text]
Inhibition of PTGS1 Promotes Osteogenic Differentiation Of
Wang et al. Stem Cell Research & Therapy (2019) 10:57 https://doi.org/10.1186/s13287-019-1167-3 RESEARCH Open Access Inhibition of PTGS1 promotes osteogenic differentiation of adipose-derived stem cells by suppressing NF-kB signaling Yuejun Wang1,2, Yunsong Liu1,2, Min Zhang1,2, Longwei Lv1,2, Xiao Zhang1,2, Ping Zhang1,2* and Yongsheng Zhou1,2* Abstract Background: Tissue inflammation is an important problem in the field of human adipose-derived stem cell (ASC)- based therapeutic bone regeneration. Many studies indicate that inflammatory cytokines are disadvantageous for osteogenic differentiation and bone formation. Therefore, overcoming inflammation would be greatly beneficial in promoting ASC-mediated bone regeneration. The present study aims to investigate the potential anti-inflammatory role of Prostaglandin G/H synthase 1 (PTGS1) during the osteogenic differentiation of ASCs. Methods: We performed TNFα treatment to investigate the response of PTGS1 to inflammation. Loss- and gain-of- function experiments were applied to investigate the function of PTGS1 in the osteogenic differentiation of ASCs ex vivo and in vivo. Western blot and confocal analyses were used to determine the molecular mechanism of PTGS1-regulated osteogenic differentiation. Results: Our work demonstrates that PTGS1 expression is significantly increased upon inflammatory cytokine treatment. Both ex vivo and in vivo studies indicate that PTGS1 is required for the osteogenic differentiation of ASCs. Mechanistically, we show that PTGS1 regulates osteogenesis of ASCs via modulating the NF-κB signaling pathway. Conclusions: Collectively, this work confirms that the PTGS1-NF-κB signaling pathway is a novel molecular target for ASC-mediated regenerative medicine. Keywords: PTGS1, NF-κB, Osteogenic differentiation, ASCs Background tissue.
[Show full text]
Downloaded from Bioscientifica.Com at 09/25/2021 12:14:58PM Via Free Access
ID: 19-0149 8 6 Q Pang et al. PHO patients with soft tissue 8:6 736–744 giant tumor caused by HPGD mutation RESEARCH The first case of primary hypertrophic osteoarthropathy with soft tissue giant tumors caused by HPGD loss-of-function mutation Qianqian Pang1,2, Yuping Xu1,3, Xuan Qi1, Yan Jiang1, Ou Wang1, Mei Li1, Xiaoping Xing1, Ling Qin2 and Weibo Xia1 1Department of Endocrinology, Key Laboratory of Endocrinology, Ministry of Health, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China 2Musculoskeletal Research Laboratory and Bone Quality and Health Assessment Centre, Department of Orthopedics & Traumatology, The Chinese University of Hong Kong, Hong Kong SAR, Hong Kong 3Department of Endocrinology, The First Affiliated Hospital of Shanxi Medicalniversity, U Taiyuan, Shanxi, China Correspondence should be addressed to L Qin or W Xia: [email protected] or [email protected] Abstract Background: Primary hypertrophic osteoarthropathy (PHO) is a rare genetic multi-organic Key Words disease characterized by digital clubbing, periostosis and pachydermia. Two genes, f primary hypertrophic HPGD and SLCO2A1, which encodes 15-hydroxyprostaglandin dehydrogenase (15-PGDH) osteoarthropathy and prostaglandin transporter (PGT), respectively, have been reported to be related to f PHO PHO. Deficiency of aforementioned two genes leads to failure of prostaglandin E2 (PGE2) f HPGD mutation degradation and thereby elevated levels of PGE2. PGE2 plays an important role in f soft tumor tumorigenesis. Studies revealed a tumor suppressor activity of 15-PGDH in tumors, such f COX2 selective inhibitor treatment as lung, bladder and breast cancers. However, to date, no HPGD-mutated PHO patients presenting concomitant tumor has been documented.
[Show full text]
S42003-021-02488-1.Pdf
ARTICLE https://doi.org/10.1038/s42003-021-02488-1 OPEN In situ imaging reveals disparity between prostaglandin localization and abundance of prostaglandin synthases ✉ Kyle D. Duncan 1,5, Xiaofei Sun 2,3,5, Erin S. Baker 4, Sudhansu K. Dey 2,3 & Ingela Lanekoff 1 Prostaglandins are important lipids involved in mediating many physiological processes, such as allergic responses, inﬂammation, and pregnancy. However, technical limitations of in-situ prostaglandin detection in tissue have led researchers to infer prostaglandin tissue dis- tributions from localization of regulatory synthases, such as COX1 and COX2. Herein, we apply a novel mass spectrometry imaging method for direct in situ tissue localization of 1234567890():,; prostaglandins, and combine it with techniques for protein expression and RNA localization. We report that prostaglandin D2, its precursors, and downstream synthases co-localize with the highest expression of COX1, and not COX2. Further, we study tissue with a conditional deletion of transformation-related protein 53 where pregnancy success is low and conﬁrm that PG levels are altered, although localization is conserved. Our studies reveal that the abundance of COX and prostaglandin D2 synthases in cellular regions does not mirror the regional abundance of prostaglandins. Thus, we deduce that prostaglandins tissue localization and abundance may not be inferred by COX or prostaglandin synthases in uterine tissue, and must be resolved by an in situ prostaglandin imaging. 1 Department of Chemistry-BMC, Uppsala University, Uppsala, Sweden. 2 Division of Reproductive Sciences, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH 45229, USA. 3 College of Medicine, University of Cincinnati, Cincinnati, OH 45221, USA.
[Show full text]
Cyclooxygenase-Independent Inhibition by Aspirin
Proc. Natl. Acad. Sci. USA Vol. 93, pp. 11091-11096, October 1996 Medical Sciences Leukocyte lipid body formation and eicosanoid generation: Cyclooxygenase-independent inhibition by aspirin (nonsteroidal antiinflammatory agents/cyclooxygenase knockout/leukotrienes/prostaglandin endoperoxide H synthase/lipoxygenase) PATRICIA T. BOZZA*, JENNIFER L. PAYNE*, ScoTr G. MORHAMt, ROBERT LANGENBACHt, OLIVER SMITHIESt, AND PETER F. WELLER*§ *Harvard Thorndike Laboratory and Charles A. Dana Research Institute, Department of Medicine, Beth Israel Hospital, Harvard Medical School, Boston, MA 02215-5491; tDepartment of Pathology, University of North Carolina, Chapel Hill, NC 27599-7525; and *Laboratory of Experimental Carcinogenesis and Mutagenesis, National Institute of Environmental Health Sciences, Research Triangle Park, NC 27709 Communicated by Seymour J. Klenbanoff, University of Washington School of Medicine, Seattle, WA, July 31, 1996 (received for review April 8, 1996) ABSTRACT Lipid bodies, cytoplasmic inclusions that de- inducible structures. Lipid bodies are prominent in leukocytes velop in cells associated with inflammation, are inducible at sites of natural and experimental inflammation, including structures that might participate in generating inflammatory leukocytes from joints of patients with inflammatory arthritis eicosanoids. Cis-unsaturated fatty acids (arachidonic and (5-7), the airways of patients with acute respiratory distress oleic acids) rapidly induced lipid body formation in leuko- syndrome (8), and casein- or lipopolysaccharide-elicited cytes, and this lipid body induction was inhibited by aspirin guinea pig peritoneal exudates (9). The formation of lipid and nonsteroidal antiinflammatory drugs (NSAIDs). Several bodies is a regulated process that involves activation of intra- findings indicated that the inhibitory effect of aspirin and cellular signaling pathways, including protein kinase C and NSAIDs on lipid body formation was independent of cycloox- phospholipase C (10, 11).
[Show full text]
Prostaglandin Signaling Regulates Nephron Segment Patterning Of
RESEARCH ARTICLE Prostaglandin signaling regulates nephron segment patterning of renal progenitors during zebrafish kidney development Shahram Jevin Poureetezadi1,2, Christina N Cheng1,2, Joseph M Chambers1,2, Bridgette E Drummond1,2, Rebecca A Wingert1,2* 1Department of Biological Sciences, University of Notre Dame, Notre Dame, United States; 2Center for Stem Cells and Regenerative Medicine, Center for Zebrafish Research, University of Notre Dame, Notre Dame, United States Abstract Kidney formation involves patterning events that induce renal progenitors to form nephrons with an intricate composition of multiple segments. Here, we performed a chemical genetic screen using zebrafish and discovered that prostaglandins, lipid mediators involved in many physiological functions, influenced pronephros segmentation. Modulating levels of prostaglandin E2 (PGE2) or PGB2 restricted distal segment formation and expanded a proximal segment lineage. Perturbation of prostaglandin synthesis by manipulating Cox1 or Cox2 activity altered distal segment formation and was rescued by exogenous PGE2. Disruption of the PGE2 receptors Ptger2a and Ptger4a similarly affected the distal segments. Further, changes in Cox activity or irx3b sim1a PGE2 levels affected expression of the transcription factors and that mitigate pronephros segment patterning. These findings show for the first time that PGE2 is a regulator of nephron formation in the zebrafish embryonic kidney, thus revealing that prostaglandin signaling may have implications for renal birth defects and other diseases. DOI: 10.7554/eLife.17551.001 *For correspondence: rwingert@ nd.edu Introduction Competing interests: The The kidney serves central functions in metabolic waste excretion, osmoregulation, and electrolyte authors declare that no homeostasis. Vertebrate kidney organogenesis is a dynamic process involving the generation of up competing interests exist.
[Show full text]
Synthase-2 2 Stem Cells by Targeting Prostaglandin E Immunoregulatory
MicroRNA-146a Negatively Regulates the Immunoregulatory Activity of Bone Marrow Stem Cells by Targeting Prostaglandin E2 Synthase-2 This information is current as of September 30, 2021. Mariola Matysiak, Maria Fortak-Michalska, Bozena Szymanska, Wojciech Orlowski, Anna Jurewicz and Krzysztof Selmaj J Immunol 2013; 190:5102-5109; Prepublished online 15 April 2013; Downloaded from doi: 10.4049/jimmunol.1202397 http://www.jimmunol.org/content/190/10/5102 http://www.jimmunol.org/ References This article cites 45 articles, 17 of which you can access for free at: http://www.jimmunol.org/content/190/10/5102.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists by guest on September 30, 2021 • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2013 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology MicroRNA-146a Negatively Regulates the Immunoregulatory Activity of Bone Marrow Stem Cells by Targeting Prostaglandin E2 Synthase-2 Mariola Matysiak, Maria Fortak-Michalska, Bozena_ Szymanska, Wojciech Orlowski, Anna Jurewicz, and Krzysztof Selmaj The molecular mechanisms that regulate the immune function of bone marrow–derived mesenchymal stem cells (BMSCs) are not known.
[Show full text]
Prostacyclin Synthesis by COX-2 Endothelial Cells
Roles of Cyclooxygenase (COX)-1 and COX-2 in Prostanoid Production by Human Endothelial Cells: Selective Up-Regulation of Prostacyclin Synthesis by COX-2 This information is current as of October 2, 2021. Gillian E. Caughey, Leslie G. Cleland, Peter S. Penglis, Jennifer R. Gamble and Michael J. James J Immunol 2001; 167:2831-2838; ; doi: 10.4049/jimmunol.167.5.2831 http://www.jimmunol.org/content/167/5/2831 Downloaded from References This article cites 36 articles, 23 of which you can access for free at: http://www.jimmunol.org/content/167/5/2831.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on October 2, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2001 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Roles of Cyclooxygenase (COX)-1 and COX-2 in Prostanoid Production by Human Endothelial Cells: Selective Up-Regulation of Prostacyclin Synthesis by COX-21 Gillian E. Caughey,2* Leslie G.
[Show full text]
Selective Inhibitors Differentially Affect Cyclooxygenase-Dependent Pial Arteriolar Responses in Newborn Pigs
0031-3998/05/5706-0853 PEDIATRIC RESEARCH Vol. 57, No. 6, 2005 Copyright © 2005 International Pediatric Research Foundation, Inc. Printed in U.S.A. Selective Inhibitors Differentially Affect Cyclooxygenase-Dependent Pial Arteriolar Responses in Newborn Pigs FERENC DOMOKI, KRISZTINA NAGY, PÉTER TEMESVÁRI, AND FERENC BARI Department of Physiology, Faculty of Medicine [F.D., K.N., F.B.], University of Szeged, Szeged, Dóm tér 10. H-6720, Hungary; Department of Pediatrics [P.T.], University Teaching Hospital, Kecskemét, P.O. Box 149, H-6001, Hungary ABSTRACT Cyclooxygenase (COX)-derived prostanoids play an impor- 560, acetaminophen and ibuprofen. In contrast, 0.3 mg/kg indo- tant role in the cerebrovascular control of newborns. In humans methacin signiﬁcantly reduced, 1 mg/kg virtually abolished the -vasodila (%20–15ف) and in the widely accepted model of piglets, both the COX-1 and vasodilation. Arterial hypotension elicited the COX-2 isoforms are expressed in cerebral arteries. However, tion that was similarly reduced by NS-398 and indomethacin but the involvement of these isoforms in cerebrovascular control is was unaltered by SC-560. Ach dose-dependently constricted pial unknown. Therefore we tested if speciﬁc inhibitors of COX-1 arterioles. This response was similarly attenuated by NS-398, and/or COX-2 would differentially affect pial arteriolar responses indomethacin, and ibuprofen, but left intact by SC-560. We to COX-dependent stimuli in piglets. Anesthetized, ventilated conclude that the assessed COX-dependent vascular reactions piglets (n ϭ 35) were equipped with a closed cranial window, appear to depend largely on COX-2 activity. However, hyper- ␮m) to capnia-induced vasodilation was found indomethacin-sensitive 100ف and changes in pial arteriolar diameters (baseline hypercapnia (ventilation with 5–10% CO2, 21% O2, balance N2), instead of a COX-dependent response in the piglet.
[Show full text]
Role of COX-2, Thromboxane A2 Synthase, and Prostaglandin I2 Synthase in Papillary Thyroid Carcinoma Growth
Modern Pathology (2005) 18, 221–227 & 2005 USCAP, Inc All rights reserved 0893-3952/05 $30.00 www.modernpathology.org Role of COX-2, thromboxane A2 synthase, and prostaglandin I2 synthase in papillary thyroid carcinoma growth Sabine Kajita, Katharina H Ruebel, Mary B Casey, Nobuki Nakamura and Ricardo V Lloyd Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, MN, USA The development of papillary thyroid carcinoma is influenced by many factors including genetic alterations, growth factors, and physical agents such as radiation. Arachidonic acid and its derivatives including prostaglandins (PG) and thromboxane along with the enzymes involved in their synthesis have been shown to influence the growth of various tumors. We analyzed the immunoreactivity for cyclooxygenase-2 (COX-2) and mRNA expression levels of the enzymes COX-2, thromboxane A2 (TXA2) synthase, and PGI2 synthase by RT- PCR in papillary carcinomas and matching normal tissues to determine the role of these enzymes in the development of papillary thyroid carcinomas. A papillary thyroid carcinoma cell line TPC-1 was also studied in vitro to determine the role of the specific COX-2 inhibitor NS-398 on COX-2 and vascular endothelial growth factor-A, since COX-2 also has a role in regulating tumor angiogenesis. RT-PCR analysis showed significant increases in TXA2 synthase mRNA levels in papillary thyroid carcinomas compared to normal thyroid tissues. Although COX-2 mRNA levels were generally increased in papillary carcinomas, the differences were not statistically significant. There were no significant differences in PGI2 synthase mRNA levels. COX-2 protein expression was greater in papillary carcinoma compared to normal thyroid tissues; however, the levels were quite variable.
[Show full text]
Studies of Prostaglandin E Formation in Human Monocytes
Faculty of Technology and Science Biomedical Sciences Sofia Karlsson Studies of prostaglandin E2 formation in human monocytes Karlstad University Studies 2009:43 Sofia Karlsson Studies of prostaglandin E2 formation in human monocytes Karlstad University Studies 2009:43 Sofia Karlsson Studies of prostaglandin E2 formation in human monocytes Licentiate thesis Karlstad University Studies 2009:43 ISSN 1403-8099 ISBN 978-91-7063-266-2 © The Author Distribution: Faculty of Technology and Science Biomedical Sciences SE-651 88 Karlstad +46 54 700 10 00 www.kau.se Printed at: Universitetstryckeriet, Karlstad 2009 ABSTRACT Prostaglandin (PG) E 2 is an eicosanoid derived from the polyunsaturated twenty carbon fatty acid arachidonic acid (AA). PGE 2 has physiological as well as pathophysiological functions and is known to be a key mediator of inflammatory responses. Formation of PGE 2 is dependent upon the activities of three specific enzymes involved in the AA cascade; phospholipase A 2 (PLA 2), cyclooxygenase (COX) and PGE synthase (PGEs). Although the research within this field has been intense for decades, the regulatory mechanisms concerning the PGE 2 synthesising enzymes are not completely established. PGE 2 was investigated in human monocytes with or without lipopolysaccharide (LPS) pre-treatment followed by stimulation with calcium ionophore, opsonised zymosan or phorbol myristate acetate (PMA). Cytosolic PLA 2α (cPLA 2α) was shown to be pivotal for the mobilization of AA and subsequent formation of PGE 2. Although COX-1 was constitutively expressed, monocytes required expression of COX-2 protein in order to convert the mobilized AA into PGH 2. The conversion of PGH 2 to the final product PGE 2 was to a large extent due to the action of microsomal PGEs-1 (mPGEs-1).
[Show full text]
Metabolism of Prostaglandins in the Kidney
View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Kidney International, Vol. 19 (1981), pp. 760—770 Metabolism of prostaglandins in the kidney FRANK F. SUN, BRUCE M. TAYLOR, JAMES C. MCGUIRE, and PATRICK Y. K. WONG Department of Experimental Biology, The Upjohn Company, Kalamazoo, Michigan, and Department of Pharmacology, New York Medical College, Valhalla, New York Since the early report of Lee et a! [1] describing a recommend that the reader consult the reviews vasoactive acidic lipid in the rabbit renal medulla, published elsewhere [4—6]. the kidney has been recognized as a major site of prostaglandin metabolism in the body. In fact, the Prostaglandin biosynthesis kidney medulla is one of the richest sources of The renal prostaglandin biosynthesis has been cyclooxygenase activity and, therefore, has been extensively investigated for over a decade [7—9], but widely used for prostaglandin biosynthetic studies. there are still many gray areas of ambiguity. In Many direct and indirect findings have established vitro, the renal papilla and medulla from rat, rabbit, that PG!2 and PGE2 play important roles in the and human [7-46] contain more cyclooxygenase regulation of renal blood flow and maintenance of (prostaglandin endoperoxide synthetase) than the electrolyte balance. Other oxygenated metabolites cortex does. The medullary cyclooxygenase is of arachidonic acid (that is, PGF2a, PGD2, TXB2, membrane bound and can be solubilized and isolat- hydroxyeicosatetraenoic acids, and leucotrienes ed by column chromatography [14]. The solubilized [2]) are reportedly synthesized by the kidney, al- enzyme has a heme-dependent cyclooxygenase ac- though their function remains as yet undefined.
[Show full text]